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Vascular erectile dysfunction (ED) and cardiovascular disease (CVD) share common risk 
factors including obesity, hypertension, metabolic syndrome, diabetes, and smoking. ED and 
CVD also have common underlying pathologic mechanisms, including endothelial 
dysfunction, inflammation, and atherosclerosis1. Despite these close relationships, evidence 
documenting ED as an independent predictor of future CVD events is limited.
We therefore leveraged the Multi-Ethnic Study of Atherosclerosis (MESA) – an ethnically-
diverse, community-based, multi-site prospective cohort study – to examine the value of 
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self-reported ED for predicting incident coronary heart disease (CHD) and CVD in those 
free of these CVD at baseline. Details of MESA have been described previously2. Male 
MESA participants who attended Visit 5, and answered the single Massachusetts Male 
Aging Study (MMAS) question3 on ED symptoms were considered for our analysis (n = 
1914). A participant was considered to have ED if he responded “Never able” or 
“Sometimes Able” to the MMAS question. After excluding 155 participants with a CVD 
event before Visit 5, 1757 participants were followed for 3.8 years (IQR 3.5–4.2) and 
outcomes of hard CHD and CVD events were assessed. Hard CVD events included all hard 
CHD events (myocardial infarction, resuscitated cardiac arrest and CHD death), plus stroke 
and stroke death. Participants provided informed consent and each study site obtained 
approval from their institutional review board.
Cox proportional hazard models were developed to calculate hazard ratios for the outcomes 
by ED status (ED yes/no) after adjusting for age, race/ethnicity and education (Model 1), 
further adjusting for smoking status, diabetes, family history of CHD, Total/HDL cholesterol 
ratio, systolic blood pressure, anti-hypertensive medication use, and lipid lowering 
medication use (Model 2), and further adjusting for beta-blocker use and depression 
assessed by the Center for Epidemiologic Studies Depression (CES-D) score (CES-D>16 vs 
≤16) (Model 3).
To further assess the potential bidirectional relationship of prior CVD with ED, an additional 
shifted-time cross-sectional analysis was conducted to see if an interim CVD event before 
MESA Visit 5 was associated with self-reported ED at Visit 5. For this analysis, all 1,914 
participants with an ED assessment were included in a multivariable-adjusted logistic 
regression adjusting for the above-mentioned covariates.
The mean age of the 1,914 participants was 69±9.2 years and 42.3% were Caucasian, 24.2% 
African American, 10.5% Chinese American and 22.9% Hispanic. ED symptoms were 
reported by 877 (45.8%) participants. Participants with ED were more likely to have 
diabetes and a family history of CHD. They were also more likely to use beta-blocker, anti-
hypertensive, lipid-lowering, and anti-depressant medications. Over the 3.8-year follow-up, 
there were a total of 40 CHD and 75 CVD hard events. A significantly greater proportion of 
participants with ED experienced hard events compared to those without ED (CHD hard 
events: 3.4% vs 1.4%, p<0.001; CVD hard events: 6.3% vs 2.6%, p<0.001).
In the unadjusted Cox models, ED was a significant predictor of both hard CHD (HR: 2.5, 
95% CI: 1.3-4.8) and CVD (HR: 2.6, 95% CI:1.6-4.1) events. In the fully adjusted models 
(Model 3), ED remained a significant predictor of hard CVD events (HR: 1.9, 95% CI: 
1.1-3.4), while hard CHD events became non-significant, albeit with a similar point estimate 
of risk (Figure).
In the shifted-time cross-sectional analysis, a significant association was also seen between 
prior CVD event and ED at visit 5 (OR: 2.1, 95% CI: 1.4-3.2) which remained significant 
but was attenuated by medication use and depression in the fully adjusted models (OR:1.7, 
95% CI: 1.1-2.6).
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In an ethnically-diverse, community-based cohort, ED was found to be a significant 
predictor of hard CVD events after adjustment for traditional CVD risk factors, depression, 
and beta-blocker use. To our knowledge, this is the first study of ED and subsequent CVD 
that adjusted for depression and beta-blocker use. Our results suggest that these two factors 
may partially mediate the relationship between prior CVD and subsequent ED, but do not 
attenuate the prospective association of ED and incident CVD. Our findings strengthen the 
existing evidence for the independent association between ED and incident CVD, and could 
have important clinical implications for risk stratification in middle-aged men. We have 
previously documented increased subclinical atherosclerosis in those who subsequently 
report ED4. In 2017, the UK QRISK score was the first to incorporate ED as an independent 
risk factor for CVD5, yet ED remains absent from U.S. risk prediction guidelines. Our 
results may justify more aggressive preventive therapy in such patients.
Our study had certain limitations. While similar to primary care assessment of ED, the 
single MMAS question does not distinguish between vascular and non-vascular types of ED, 
which may have attenuated the association between ED and CVD. Additionally, since our 
follow-up was just 3.8 years, additional 10-year data on the risk predictive value of ED are 
needed.
In conclusion, our study provides some of the strongest evidence to date for the independent 
predictive value of ED in a modern, multi-ethnic, well-phenotyped cohort.
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Figure. Association between ED and incident CHD and CVD hard events among 1,757 male 
MESA participants
A and B, Kaplan-Meier cumulative survival function curves for hard CHD and CVD events 
by ED status. C, Cox proportional hazard ratios (95% CIs) of hard CHD and CVD events by 
ED status. *P value by log-rank testing. †Model 1 adjusted for age, race/ethnicity and 
education. ‡ Model 2 adjusted for Model 1 + smoking status, diabetes, family history of 
CHD, Total/HDL cholesterol ratio, systolic blood pressure, anti-hypertensive medication use 
and lipid lowering medication use. §Model 3 adjusted for Model 2 + depression and beta 
blocker use. CHD indicates coronary heart disease; CI, confidence interval; CVD, 
cardiovascular disease; ED, erectile dysfunction; and HDL, high-density lipoprotein.
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